Moderna (NASDAQ:MRNA) Cut to Equal Weight at Barclays

Barclays downgraded shares of Moderna (NASDAQ:MRNA) from an overweight rating to an equal weight rating in a report published on Tuesday, MarketBeat Ratings reports. The firm currently has $45.00 price target on the stock, down from their previous price target of $111.00.

MRNA has been the topic of several other reports. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. UBS Group reduced their price target on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase & Co. reduced their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a report on Tuesday, November 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, November 8th. Finally, Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.58.

Moderna Stock Performance

Shares of MRNA opened at $35.72 on Tuesday. The company’s fifty day moving average price is $38.61 and its 200 day moving average price is $53.82. The company has a market capitalization of $13.75 billion, a PE ratio of -6.14 and a beta of 1.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a one year low of $29.25 and a one year high of $170.47.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last three months. 15.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its holdings in shares of Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after buying an additional 574 shares during the period. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares in the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna in the fourth quarter worth $37,000. Finally, Larson Financial Group LLC lifted its position in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.